Thoughts on Bayer’s and Atara’s Collaboration to Develop Solid Tumor CAR-T Therapies

On Sunday, December 6, Bayer and Atara Biotherapeutics announced (Bayer press release / Atara press release) a collaboration and worldwide license agreement. The collaboration covers research, development, and manufacturing milestones for mesothelin-targeting CAR-T therapies in high mesothelin-expressing solid tumors. Of note, the agreement includes the development of ATA2271 (an autologous mesothelin-targeting CAR-T) and its allogeneic version ATA3271 to treat malignant pleural mesothelioma and non-small-cell lung cancer. Below, Celltelligence provides thoughts on Bayer’s growing cell therapy portfolio, a possible strategy for advancing cell therapies, and if they will license Atara’s allogeneic CD19 CAR-T.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.